Kuros Biosciences AG
KURN.SW News Today: Stay Updated with the Latest Kuros Biosciences AG News in Real Time
Find KURN.SW news now at Meyka AI. Stay informed with the latest Kuros Biosciences AG stocks updates, including price news, market analysis, and expert insights.
Pre-market loser KURN.SW Kuros Biosciences SIX Mar 2026 -6.14%: valuation risk
Pre-market look at KURN.SW stock down -6.14% on 25 Mar 2026 with Meyka AI forecast and valuation insight
Pre-Market Top Loser: GNCA stock at $0.0001 on NASDAQ, Chapter 11 fallout to watch
Pre-market: GNCA stock at $0.0001 on NASDAQ on 19 Mar 2026; Chapter 11 history, low liquidity, and Meyka AI forecast
C$0.035 WLLW.TO Willow Biosciences (TSX) market closed 18 Mar 2026: bounce risk
WLLW.TO stock closed C$0.035 on TSX 18 Mar 2026 with heavy volume and an oversold bounce setup
Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026
Jefferies keeps Buy; DTIL analyst rating notes price target cut to $19 and near-term setup attractive
Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026
Raymond James reiterates Strong Buy for Cogent; COGT analyst rating held on March 16, 2026 with market implications
H.C. Wainwright Maintains Buy on NovaBridge Biosciences (NBP) Mar 16, 2026
NBP analyst rating: H.C. Wainwright maintains Buy on Mar 16, 2026 with $9 price target and Meyka AI grade B+
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026
Cowen maintained Buy on MBX Biosciences; MBX analyst rating held on March 12, 2026 with market cap and investor takeaways
KURN.SW down 8.79% at close 12 Mar 2026 (Market closed, CHF25.94): outlook
KURN.SW stock falls 8.79% to CHF25.94 on 12 Mar 2026. Meyka AI forecast CHF34.56 yearly, model-based projection
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026
NBIX analyst rating: Cantor Fitzgerald maintained Overweight and raised PT to $195 on March 10, 2026